Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-17 · accession 0000899243-21-036432 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-17 | 2021-09-17 | TYRA | Bensen Daniel | COO | C - Cnv Deriv | — | +8,501 | 528.0K | +2% | — |
| D | 2021-09-17 | 2021-09-17 | TYRA | Bensen Daniel | COO | C - Cnv Deriv | $0.00 | -3,273 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-17 | C | A | 8,501 | — | 527,981 | D | — | — | (F1) On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| 2 | Derivative | Series A Preferred Stock | 2021-09-17 | C | D | 3,273 | $0.00 | 0 | D | — · — to — | 8,501 Common Stock | (F1) On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |